Adamas Pharmaceuticals Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Adamas Pharmaceuticals stock.
View analyst ratings for Adamas Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Adamas Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adamas Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Adamas Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Adamas Pharmaceuticals.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) posted its earnings results on Sunday, May, 9th. The specialty pharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.15. The specialty pharmaceutical company earned $19.31 million during the quarter, compared to analysts' expectations of $19.59 million.
View Adamas Pharmaceuticals' earnings history.

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADMS stock has increased by 70.5% and is now trading at $5.20.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued twelve-month price targets for Adamas Pharmaceuticals' shares. Their forecasts range from $6.00 to $12.50. On average, they anticipate Adamas Pharmaceuticals' share price to reach $10.17 in the next twelve months. This suggests a possible upside of 95.5% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals or view top-rated stocks among Wall Street analysts.

2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Adamas Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Merus (MRUS), ADVANZ PHARMA (CXRXF), Verastem (VSTM), Zomedica (ZOM), Collegium Pharmaceutical (COLL), Karyopharm Therapeutics (KPTI), Praxis Precision Medicines (PRAX), Affimed (AFMD), Silence Therapeutics (SLN), Crinetics Pharmaceuticals (CRNX), Xenon Pharmaceuticals (XENE), Evolus (EOLS), IDEAYA Biosciences (IDYA) and Pharming Group (PHAR).
View all of ADMS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Adamas Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.32%), Opaleye Management Inc. (4.04%), Renaissance Technologies LLC (1.96%), Cooper Creek Partners Management LLC (1.93%), BlackRock Inc. (1.33%) and Worth Venture Partners LLC (1.30%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Martha J Demski, Spyridon Papapetropoulos and Vijay Shreedhar.
View institutional ownership trends for Adamas Pharmaceuticals.

ADMS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, D. E. Shaw & Co. Inc., Deltec Asset Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, and Assenagon Asset Management S.A.. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, Martha J Demski, and Vijay Shreedhar.
View insider buying and selling activity for Adamas Pharmaceuticals or view top insider-selling stocks.

ADMS stock was bought by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Cooper Creek Partners Management LLC, Altium Capital Management LP, Worth Venture Partners LLC, Monashee Investment Management LLC, Opaleye Management Inc., Millennium Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Adamas Pharmaceuticals or or view top insider-buying stocks.

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMS stock can currently be purchased for approximately $5.20.

Adamas Pharmaceuticals has a market capitalization of $215.11 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57,400,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

Adamas Pharmaceuticals employs 138 workers across the globe.

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

Adamas Pharmaceuticals is headquartered at 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608.

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]